Personalizing Medicine through AI

About PreciseDx

PreciseDx is an augmented intelligence healthcare services provider delivering patient-specific insights that aid in disease state characterization and enable better treatment decisions and outcomes. Our pipeline addresses high-impact areas such as breast cancer.

Integrating artificial intelligence, lab processes and workflow systems
Transforming clinical modeling, patient phenotyping & image analysis
Providing unmatched insights to support pathologists & oncologists

Better Data. Better Outcomes.

PreciseDx’s AI-powered predictive platform creates disease-specific assays that deliver new levels of patient risk information to drive benefits across the healthcare continuum.

  • Patients
  • Providers
  • Payers
  • BioPharma

The PreciseDx platform enables individualized treatment plans and supports improved patient outcomes.

For providers, PreciseDx delivers highly accurate risk profiles, enables diagnostic precision, reduces error rates and decreases costs.

By providing accurate risk profiles for each individual patient, PreciseDx enables decreased costs for payers.

The PreciseDx AI platform is available for biopharmaceutical research and development, enabling researchers to leverage AI insights and data derived from high-volume, well-annotated study populations.

Patients

The PreciseDx platform enables individualized treatment plans and supports improved patient outcomes.

Providers

For providers, PreciseDx delivers highly accurate risk profiles, enables diagnostic precision, reduces error rates and decreases costs.

Payers

By providing accurate risk profiles for each individual patient, PreciseDx enables decreased costs for payers.

BioPharma

The PreciseDx AI platform is available for biopharmaceutical research and development, enabling researchers to leverage AI insights and data derived from high-volume, well-annotated study populations.

Investors & Partners

PreciseDx completed a significant financing round in early 2021 with investments from world-class strategic and financial investors. PreciseDx is collaborating with several of these investors on its development, testing, and marketing efforts.

Featured Media

Publications
December 8, 2020
San Antonio Breast Cancer Symposium
Publications
May 15, 2020
American Urological Association
Publications
December 10, 2019
San Antonio Breast Cancer Symposium

Contact Us

To get in touch with us, or to request more information about the PreciseDx breast test, email us at info@precisedx.ai.

646-818-9330
info@precisedx.ai